MD Anderson Cancer center at Cooper

Camden, New Jersey 08103

7 studies enrolling now · 27 studies all time

What they study most

Adenocarcinoma of the Pancreas, Advanced Melanoma, Brain Metastases, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Breast Atypical Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Cancer, Breast Carcinoma, Breast Lobular Carcinoma in Situ, Breast Neoplasms, Cancer, Candidates for BRCA 1/2 Genetic Testing

Studies at this site

• Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types — Recruiting now
• Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy — Recruiting now
• Testing Gene PilotLX With Latinx Cancer Patients — Recruiting now
• A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) — Running, not enrolling
• A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer — Running, not enrolling
• Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release — Available (expanded access)
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer — Stopped early
• Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk — Stopped early
• Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). — Completed
• Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian — Completed
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) — Completed
• Stereotactic Radiosurgery for Soft Tissue Sarcoma — Withdrawn before enrolling
• A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study — Completed
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) — Completed
• A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer — Stopped early
• Stereotactic Radiosurgery (SRS) for Multiple CNS Mets — Withdrawn before enrolling
• Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) — Stopped early
• Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer — Status unconfirmed
• Insomnia Interventions in Cancer Survivors — Status unconfirmed
• A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer — Status unconfirmed